Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (KCT0012323) titled 'Net Clinical Benefit of Edoxaban versus Apixaban in Patients with Atrial Fibrillation and Coronary Artery Disease' on July 23.
Study Type: Interventional Study
Study Design:
Primary Purpose : Supportive Care, Intervention Model : Parallel, Blinding/Masking : Open, Allocation : RCT
Primary Sponsor: Samsung Medical Center
Condition:
Diseases of the circulatory system
Intervention:
Drug : A total of 3,000 patients (1,500 in the edoxaban-based treatment group and 1,500 in the apixaban-based treatment group) will be recruited from participating multicenter sites in Korea. The study is intended for patients with atria...